Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Saved in:
| Title: | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. |
|---|---|
| Authors: | Sharma M; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khong H; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fa'ak F; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bentebibel SE; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Janssen LME; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chesson BC; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Creasy CA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Forget MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kahn LMS; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pazdrak B; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karki B; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hailemichael Y; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh M; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vianden C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vennam S; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Bharadwaj U; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA., Tweardy DJ; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA., Haymaker C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bernatchez C; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang S; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Dan L. Duncan Cancer Center, Houston, TX, USA., Rajapakshe K; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA., Hurwitz ME; Yale Comprehensive Cancer Center, New Haven, CT, USA., Sznol M; Yale University Cancer Center, Yale University, New Haven, CT, USA., Hwu P; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hoch U; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Addepalli M; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Charych DH; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Zalevsky J; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA., Diab A; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Overwijk WW; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.; Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. woverwijk@nektar.com.; The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA. woverwijk@nektar.com.; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com. |
| Source: | Nature communications [Nat Commun] 2020 Jan 31; Vol. 11 (1), pp. 661. Date of Electronic Publication: 2020 Jan 31. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
